Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2010-01-08
2010-10-19
Padmanabhan, Sreeni (Department: 1627)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S354000, C514S640000, C514S646000
Reexamination Certificate
active
07816383
ABSTRACT:
The present invention relates to methods involving avoiding adverse drug interactions with fluvoxamine and pirfenidone or other moderate to strong inhibitors of CYP enzymes.
REFERENCES:
patent: 5310562 (1994-05-01), Margolin
patent: 5518729 (1996-05-01), Margolin
patent: 5716632 (1998-02-01), Margolin
patent: 7407973 (2008-08-01), Ozes et al.
patent: 7566729 (2009-07-01), Bradford et al.
patent: 2006/0110358 (2006-05-01), Hsu
patent: 2007/0053877 (2007-03-01), Crager et al.
patent: 2007/0054842 (2007-03-01), Blatt et al.
patent: 2007/0072181 (2007-03-01), Blatt
patent: 2007/0092488 (2007-04-01), Strieter et al.
patent: 2007/0117841 (2007-05-01), Ozes et al.
patent: 2007/0172446 (2007-07-01), Blatt
patent: 2007/0203202 (2007-08-01), Robinson et al.
patent: 2007/0203203 (2007-08-01), Tao et al.
patent: 2008/0019942 (2008-01-01), Seiwert et al.
patent: 2008/0194644 (2008-08-01), Bradford
patent: 2008/0287508 (2008-11-01), Robinson et al.
patent: 2009/0170804 (2009-07-01), Phillips et al.
patent: 2009/0197923 (2009-08-01), Bradford
Hemeryck et al. 2002, Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: An update, Current Drug Metabolism, vol. 3, pp. 13-37.
Remington's: the Science and Practice of Pharmacy, Nineteenth Edition, vol. 1, p. 806.
Azuma et al., Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis.Am. J. Respir. Crit. Care Med.171: 1040-7 (2005).
Shionogi & Co., Ltd., Pirespa Tablet Packaging Label, Prepared Oct. 2008.
Shionogi & Co., Ltd., Pirespa Tablet Report on the Deliberation Results, Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare (Sep. 16, 2008).
Correspondence received from FDA.
BuSpar® (buspirone HCI, USP) package insert.
Clozaril® (clozapine) package insert.
Dolophine® Hydrochloride (methadone hydrochloride) package insert.
Inderal® (propranolol hydrochloride capsule, extended release) package insert.
Inderal® (propranolol hydrochloride, long-acting capsules) package insert.
Lexotan® (bromazepam) package insert.
Malarone® (atovaquone and proguanil hydrochloride) package insert.
Mexitil® (mexiletine hydrochloride, USP) package insert.
Naropin® (ropivacaine hydrochloride monohydrate) package insert.
Quinidine Gluconate package insert.
Thioridazine Hydrochloride package insert.
Tofranil (imipramine hydrochloride) package insert.
Food and Drug Administration Center for Drug Evaluation and Research, Pulmonary-Allergy Drugs Advisory Committee (PADAC) Meeting Transcript (Tuesday, Mar. 9, 2010), published at http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Pulmonary-AllergyDrugsAdvisoryCommittee/UCM208806.pdf.
Pirfenidone NDA 22-535 Pulmonary-Allergy Drugs Advisory Committee Mar. 9, 2010, slide deck (InterMune, Inc.), published at http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Pulmonary-AllergyDrugsAdvisoryCommittee/UCM206399.pdf.
Pulmonary-Allergy Drugs Advisory Committee Meeting, Pirfenidone Capsules, NDA 22-535, S-000, Mar. 9, 2010, slide deck (U.S. Food and Drug Administration), published at http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Pulmonary-AllergyDrugsAdvisoryCommittee/UCM206398.pdf.
FDA Briefing Information for the Mar. 9, 2010 Meeting of the Pulmonary-Allergy Drugs Advisory Committee (Contains the Clinical Briefing Document (Banu Karimi-Shah, M.D., Clinical Reviewer, Division of Pulmonary and Allergy Products, NDA 22-535) beginning on p. 21), published at http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Pulmonary-AllergyDrugsAdvisoryCommittee/UCM203081.pdf.
European search report from EP 10250379.4 dated May 17, 2010.
InterMune Briefing Information for the Mar. 9, 2010 Meeting of the Pulmonary-Allergy Drugs Advisory Committee, published at http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Pulmonary-AllergyDrugsAdvisoryCommittee/UCM203083.pdf.
Jeppesen et al., “Dose-dependent inhibition of CYPIA2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluovaxamine and paroxetine,” European Journal of Clinical Pharmacology, 51(1):73-78 (1996).
Landi, et al., “Human cytochrome P4501A2.” IARC Scientific Publications 148:173-195(1999).
Bradford Williamson Ziegler
Szwarcberg Javier
Bendrick John A.
Intermune, Inc.
Marshall & Gerstein & Borun LLP
McMillian Kara R
Padmanabhan Sreeni
LandOfFree
Methods of administering pirfenidone therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of administering pirfenidone therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of administering pirfenidone therapy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4181179